FIRST EXTENSION - GRANTED
granted
on 09 Sep 2024
Last Applicant/ Owned by
350 Fifth Avenue, Suite 5330
New York
NY
10118
Serial Number
97703809 filed on 05th Dec 2022
Registration Number
N/A
Correspondent Address
Mark A. Jansen
Filing Basis
1. intent to use
2. intent to use current
Disclaimer
NO DATA
CANCER ZERO
Research, development, and evaluation of new products; pharmaceutical, medicine, and vaccine research and development services; technical research in the field of pharmaceutical studies; laboratory analysis and research into new drugs and pharmaceutical products; development of scientific measuring and testing methods in the field of oncology; design, development, research, and conducting clinical Read More
Classification Information
Class [044]
Medical, Beauty & Agricultural Services
Medical services; Providing health information; Providing health information in the field of bioengineering and genetic engineering; Providing health information in the field of autoimmune, inflammatory and infectious diseases and disorders, cancer prevention and treatment; Medical diagnosis and treatment of cancer, autoimmune, inflammatory, and infectious diseases and disorders
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [042]
Computer & Software Services & Scientific Services
Research, development, and evaluation of new products; pharmaceutical, medicine, and vaccine research and development services; technical research in the field of pharmaceutical studies; laboratory analysis and research into new drugs and pharmaceutical products; development of scientific measuring and testing methods in the field of oncology; design, development, research, and conducting clinical trials for others in connection with drugs, pharmaceuticals, and cellular therapies for the treatment and/or prevention of cancer; research and development services in the fields of oncology, immunotherapy, chemotherapy and combination therapies for the treatment of cancer and tumors; providing medical research information in the fields of oncology, immunotherapy, chemotherapy and combination therapies; scientific advisory services, namely, providing scientific information, advice and consultancy in the field of oncology; research and development in the field of bioengineering and genetic engineering; Research and development of treatments and therapies in the field of oncology; Research and development of pharmaceuticals for the treatment and prevention of cancer, autoimmune, inflammatory, and infectious diseases and disorders; Scientific research for medical purposes in the field of cancer, autoimmune, inflammatory, and infectious diseases and disorders; Molecular, cellular, and genetic research and development; Development of processes and methods for the manufacturing and engineering of cells and molecules; development of therapeutics and treatments for the prevention of cancer, autoimmune, inflammatory, genetic and infectious diseases and disorders; Development of diagnostic medical measuring and testing methods in the field of cancer therapy and treatment
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Pharmaceutical preparations, namely, oncological preparations; reagent, diagnostic and therapeutic preparations for medical use in oncology; targeted medical preparations for use in oncology; pharmaceutical preparations for use in the treatment of cancer and tumors; pharmaceutical and medicinal preparations for the treatment of cancer and oncological conditions; pharmaceutical and biological preparations for use in immunotherapies to improve immune system function; pharmaceutical and biological preparations combining immunotherapies and chemotherapies for treatments in the field of oncology; medical and veterinary preparations for the delivery of compounds to the body for the treatment and prevention of immunological and oncological diseases and disorders; pharmaceutical and biological preparations comprised of modified t cells used for multiple modes of treatment against tumor resistance and immunosuppression; pharmaceuticals in the nature of cell therapeutics for the treatment and prevention of cancer; engineered cell therapies, namely, engineered T cells, immune cells, and antibodies for the treatment and prevention of cancer
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 97703809
Mark Type
No Service Mark
Attorney Docket Number
No 37070-00070
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 09th Sep 2024 | SOU EXTENSION 1 GRANTED |
| 09th Sep 2024 | SOU EXTENSION 1 FILED |
| 09th Sep 2024 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| 09th Sep 2024 | SOU TEAS EXTENSION RECEIVED |
| 12th Mar 2024 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| 16th Jan 2024 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| 16th Jan 2024 | PUBLISHED FOR OPPOSITION |
| 27th Dec 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| 13th Dec 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| 12th Dec 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |